Toyama Chemical Applies For Approval Of Pediatric Antimicrobial Agent
This article was originally published in PharmAsia News
Toyama Chemical applied for approval of Ozex powder for pediatric use. A newquinolone antimicrobial agent, the drug is indicated to treat pediatric pneumonia and otitis media. Ozex pediatric is based on the Ozex tablet that was developed and launched by the company in 1990. Toyama Chemical changed the tablet into powder for easier adjustment in dosage. Upon approval, Ozex pediatric will be the first newquinolone antimicrobial agent to treat pediatric pneumonia in Japan. (Click here for more - Japanese language
You may also be interested in...
Mooted some time ago, the Medicare Part D Drug Rebate Rule and the Medicare Part B Most-Favored-Nation Model have now been finalized by US President Donald Trump. But US off-patent body the Association for Accessible Medicines feels “further action is necessary.”
Lannett will launch a further seven products in fiscal 2021, after launching four products recently in the first quarter of FY21. The company also plans to pay off its Term Loan ‘A’ in full, by the end of November 2020.
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.